Diagnosis and Management of Waldenstrom’s Macroglobulinemia
9.4 هزار بار بازدید -
2 سال پیش
-
00:00
00:00 - Diagnosis and Management of Waldenstrom’s Macroglobulinemia
02:13- What is Waldenstrom's Macroglobulinemia (WM)?
03:50- How is Waldenstrom's Macroglobulinemia diagnosed?
07:21- Is monitoring instead of intervention an option at all for WM?
12:51- How do MYD88 wildtype or CXCR4 mutations affect treatment decisions for WM?
15:26- Novel therapies that may impact the standard of care for WM
21:44- What is the eligibility criteria for the CLOVER trial?
23:56- Are BTK inhibitors appropriate to use as a first-line therapy in WM?
27:54- Side effects of alkylating agents and BTK inhibitors
35:34- Are WM patients living longer with novel therapies getting approved?
38:27- How does CLR-131 work?
40:41- Educating patients about clinical trials and treatment options
43:49- Cost effectiveness of novel therapies for Waldenstrom's Macroglobulinemia
Waldenstrom’s macroglobulinemia (WM) is a rare type of cancer that begins in the white blood cells.The abnormal white blood cells produce a protein that accumulates in the blood, impairs circulation and causes complications. It continues to be a clinical challenge for treating physicians as complete remissions and prevention of relapse are few in spite of all the therapeutic tools that are currently available. Besides treatment aspects, correct diagnosis of WM often poses a challenge.
We are talking to the Clinical Director at Bing Center for Waldenström Macroglobulinemia, Dr. Jorge J. Castillo about WM management touching upon diagnosis, when not to get treated, current clinical trials and more. Joining us bringing in the patient perspective is patient advocate and IWMF Trustee, Peter DeNardis.
This talk has been created by CureTalks.com, in association with Cellectar BioSciences to facilitate discussions for solutions, with a mission to heal the world through information and sharing of knowledge. At CureTalks we discuss groundbreaking medical research including a wide range of medical, health, and wellness issues, bringing together the doctors, researchers and patients on the same platform.
#DiagnosisWaldenstrom’s #Macroglobulinemia #CareforWaldenstrom
SUBSCRIBE!
https://www.seevid.ir/c/CureTalks?s...
LET'S CONNECT!
Website: https: https://www.curetalks.com/
Facebook: Facebook: CureTalks
Instagram: Instagram: cure_talks_tx
Linkedin: https://www.linkedin.com/company/cure...
Twitter : Twitter: curetalks
Pinterest: Pinterest: _saved
02:13- What is Waldenstrom's Macroglobulinemia (WM)?
03:50- How is Waldenstrom's Macroglobulinemia diagnosed?
07:21- Is monitoring instead of intervention an option at all for WM?
12:51- How do MYD88 wildtype or CXCR4 mutations affect treatment decisions for WM?
15:26- Novel therapies that may impact the standard of care for WM
21:44- What is the eligibility criteria for the CLOVER trial?
23:56- Are BTK inhibitors appropriate to use as a first-line therapy in WM?
27:54- Side effects of alkylating agents and BTK inhibitors
35:34- Are WM patients living longer with novel therapies getting approved?
38:27- How does CLR-131 work?
40:41- Educating patients about clinical trials and treatment options
43:49- Cost effectiveness of novel therapies for Waldenstrom's Macroglobulinemia
Waldenstrom’s macroglobulinemia (WM) is a rare type of cancer that begins in the white blood cells.The abnormal white blood cells produce a protein that accumulates in the blood, impairs circulation and causes complications. It continues to be a clinical challenge for treating physicians as complete remissions and prevention of relapse are few in spite of all the therapeutic tools that are currently available. Besides treatment aspects, correct diagnosis of WM often poses a challenge.
We are talking to the Clinical Director at Bing Center for Waldenström Macroglobulinemia, Dr. Jorge J. Castillo about WM management touching upon diagnosis, when not to get treated, current clinical trials and more. Joining us bringing in the patient perspective is patient advocate and IWMF Trustee, Peter DeNardis.
This talk has been created by CureTalks.com, in association with Cellectar BioSciences to facilitate discussions for solutions, with a mission to heal the world through information and sharing of knowledge. At CureTalks we discuss groundbreaking medical research including a wide range of medical, health, and wellness issues, bringing together the doctors, researchers and patients on the same platform.
#DiagnosisWaldenstrom’s #Macroglobulinemia #CareforWaldenstrom
SUBSCRIBE!
https://www.seevid.ir/c/CureTalks?s...
LET'S CONNECT!
Website: https: https://www.curetalks.com/
Facebook: Facebook: CureTalks
Instagram: Instagram: cure_talks_tx
Linkedin: https://www.linkedin.com/company/cure...
Twitter : Twitter: curetalks
Pinterest: Pinterest: _saved
2 سال پیش
در تاریخ 1401/08/09 منتشر شده
است.
9,492
بـار بازدید شده